Rapamycin

Rapamycin is a prescription immunosuppressant sold under the generic name sirolimus. Clinicians use it to stop the immune system rejecting a transplanted kidney, and to treat a rare lung disease called lymphangioleiomyomatosis (LAM). It works by blocking a cell growth switch called mTOR. It is not approved as an anti-aging treatment.

Most people reading about this drug are not transplant patients. They have heard that an old transplant medicine extended life in laboratory mice, and they want to know what that means for a person. This page keeps three things apart: what the US label actually approves, what the longevity research does and does not show, and what an off-label prescription involves in money, labs and risk.

What this drug is, and why one molecule has three names

The story starts with a soil sample from Rapa Nui, also called Easter Island. Researchers found a bacterium, Streptomyces hygroscopicus, that made a compound with antifungal activity. They named the compound after the island. Later work showed it damped down the immune system, so it was developed as a transplant drug instead of an antifungal.

The names line up like this:

• Rapamycin is the original laboratory name, still used in research papers.
• Sirolimus is the official generic drug name used on US prescriptions and labeling.
• Rapamune is the original brand name for the oral tablets and oral solution.

So sirolimus versus rapamycin is not a real comparison. They are the same molecule. Brand versus molecule is the only difference in the other pairing, much like the relationship between Tylenol and acetaminophen. Generic sirolimus tablets are also on the US market.

A family of related drugs, called rapalogs, was built from the same chemistry. Everolimus and temsirolimus are used in cancer and transplant care. There is also a topical sirolimus gel approved for skin growths in tuberous sclerosis complex, and an injectable protein-bound form of sirolimus approved for a rare soft tissue tumor. These are separate products with separate labels and they are not interchangeable. Current US labeling for each form, including full prescribing information, is published in the DailyMed label database. If you are checking how one molecule relates to others in the same space, you can Browse Medication Guides for the plain-English version of each.

How it works: the mTOR switch in plain English

Every cell has to choose between growing and conserving. A protein complex called mTOR, short for mechanistic target of rapamycin, makes that call. When food, insulin and amino acids are plentiful, mTOR switches on and cells build proteins, divide and store energy. When supply is short, mTOR quiets down and cells shift into repair mode, including a recycling process called autophagy.

This drug binds to a small protein inside the cell called FKBP12. That pair then blocks one arm of mTOR, known as mTORC1. Two consequences follow. Immune cells, especially T cells and B cells, stop multiplying as quickly, which is exactly what transplant medicine wants. And the growth-versus-repair balance tips toward repair, which is what the aging research field finds interesting. Published reviews of rapalogs in human aging describe this as the best studied drug approach to mimicking calorie restriction.

Worth holding on to: immunosuppression and the aging effects come from the same mechanism. You cannot switch one on and leave the other off. That is the central trade-off on this page.

Approved uses on the US label

The oral form carries two indications:

• Prevention of kidney transplant rejection. The label covers patients 13 years and older who have received a kidney transplant, used together with cyclosporine and corticosteroids in the regimens the prescribing information describes.
• Treatment of lymphangioleiomyomatosis. LAM is a rare lung disease that mostly affects women, in which abnormal smooth muscle-like cells grow through lung tissue and cause cysts, breathlessness and lung collapse. For this use the label describes a fixed low daily dose, with drug levels in the blood measured and kept inside the target range the label specifies.

Two other approved products use the same active ingredient in different forms: a topical gel for facial angiofibromas linked to tuberous sclerosis complex, and an albumin-bound injection for an advanced malignant PEComa. Each has its own label, dosing and warnings.

Everything else is off-label. That includes healthy aging, general cancer prevention, autoimmune conditions and cosmetic goals. Off-label prescribing by a licensed clinician is legal in the United States and is sometimes well supported by published evidence. It is not, however, an FDA review. When a use is off-label, no regulator has assessed whether the benefit outweighs the risk at that dose, in that population, over that length of time.

The longevity claim: what the evidence supports, and what it does not

The animal data are strong and repeatable. The National Institute on Aging tested this compound in genetically diverse mice across multiple laboratories and found longer median and maximum lifespan, holding up at different doses and different starting ages. That program, the Interventions Testing Program run by the NIA, was designed specifically to weed out results that only work in one lab or one mouse strain.

Human evidence is much thinner. Trials in healthy older adults have been small and short, from a few weeks to about a year, and they measured surrogate markers rather than lifespan: immune response to vaccination, skin and muscle changes, blood test shifts, self-reported function. A 48-week randomized study of intermittent low-dose treatment in healthy adults reported that it was generally tolerated, with limited and inconsistent effects on the measures tracked. Detailed reviews of the off-label case reach a similar conclusion, describing the evidence as promising but not yet proof of benefit in healthy people, and even enthusiastic scientific opinion pieces on the topic stop short of claiming a demonstrated human lifespan effect.

The practical consequence matters more than the debate. No dose, schedule or blood level has been established for healthy aging. Longevity clinics often use weekly or intermittent dosing, on the theory that spacing doses spares day-to-day immune function. That schedule appears nowhere on the label, and long-term safety data in healthy adults taking it for years do not exist. Anyone using it this way is accepting a documented risk profile in exchange for a benefit that has not been shown in people.

Two related questions come up constantly. Metformin is not the same drug: it is a diabetes medicine that works mainly on liver glucose output and insulin sensitivity, and it is studied separately in aging research, as covered in our Metformin Uses And Safety page. And veterinary use is a genuine research area, with a trial run through the Dog Aging Project, but dog findings do not transfer to humans, and any pet dosing is a veterinarian’s decision.

One more distinction, because it costs people money. Products sold online as a rapamycin supplement do not contain this drug. It is prescription only in the United States. Supplements marketed as mTOR support usually hold plant extracts, and supplement claims are not evaluated by the FDA before sale. A website offering the drug itself with no prescription and no clinician is telling you something about the seller, not offering a shortcut.

Side effects at transplant doses and at low off-label doses

Almost all the frequency data come from transplant patients taking it daily alongside other immunosuppressants, so read the list with that setting in mind. Commonly reported effects include:

• Mouth sores and inflammation, called stomatitis, the most recognizable effect of the drug
• Acne-like rash and other skin problems
• Swelling in the legs, ankles or feet, called peripheral edema
• Higher cholesterol and higher triglycerides
• Higher blood pressure
• Headache, nausea, abdominal pain and diarrhea
• Low red blood cell counts (anemia) and low platelets
• Joint pain
• Rising creatinine, a blood marker used to track kidney function
• Infections, including urinary tract infections
• Slow or incomplete wound healing
• Nosebleeds, reported in the LAM studies

Low dose rapamycin side effects, meaning the small intermittent doses used off-label, are less well characterized. What small studies and clinic reports describe leans toward mouth ulcers, minor infections such as colds and cold sores, digestive upset, and lipid changes that show up on bloodwork before you feel anything. Less drug generally means less immunosuppression. Lower risk is not the same as no risk, and the multi-year picture in healthy adults has not been studied.

Serious problems documented in the labeling include lung inflammation (interstitial lung disease or pneumonitis), fluid collections around the lungs or a transplanted kidney, a serious clotting disorder when combined with a calcineurin inhibitor, severe allergic reactions including angioedema, and a raised long-term risk of lymphoma and skin cancer that follows from suppressing immune surveillance. These appear in full in the warnings and precautions section of the prescribing information.

Boxed warnings, who should not take it, and what gets monitored

The oral label carries a boxed warning, the most serious warning class the FDA applies. It covers two things. First, immunosuppression increases susceptibility to infection and the possible development of lymphoma. Second, the drug is not recommended in liver or lung transplant recipients: studies found excess mortality and graft loss, including hepatic artery thrombosis after liver transplant and breakdown of the airway join after lung transplant.

It is contraindicated in anyone with known hypersensitivity to sirolimus. Beyond that, the label flags groups who need caution or avoidance. That includes people who:

• have an active, serious or uncontrolled infection
• are pregnant or trying to conceive, since the label warns of fetal harm and advises effective contraception before, during and for a period after stopping
• are breastfeeding
• have surgery planned or a wound that has not healed
• are men concerned about fertility, because impaired sperm production has been reported
• have received a liver or lung transplant
• have significant lung disease, poorly controlled cholesterol or triglycerides, or kidney impairment with protein in the urine
• need a live vaccine, which is generally avoided during treatment
• already take a strong inhibitor or inducer of the CYP3A4 enzyme

Monitoring is part of the treatment, not an optional add-on. Typical checks include drug levels in whole blood, a complete blood count, kidney function and urine protein, liver tests, lipids, blood sugar and blood pressure, plus regular skin checks and consistent sun protection. A program that prescribes without labs is skipping the part that catches problems early. Patient-friendly summaries of what to watch for on any immunosuppressant are also available through the MedlinePlus drug information library.

Lipids deserve their own line, since rising cholesterol and triglycerides are among the most common lab changes. If you already have a panel in hand, turning the raw numbers into ratios makes the trend between blood draws much easier to read.

Interactions and foods that change blood levels

This drug is broken down by the CYP3A4 enzyme and moved around by a transporter called P-glycoprotein. Anything that speeds up or slows that machinery changes how much drug is in your blood, sometimes dramatically.

Levels can climb with strong CYP3A4 inhibitors. Examples named in the labeling include azole antifungals such as ketoconazole, itraconazole and voriconazole, macrolide antibiotics such as clarithromycin and erythromycin, ritonavir-containing antivirals, and the heart drugs diltiazem and verapamil. Grapefruit and grapefruit juice act the same way and are avoided during treatment.

Levels can fall with strong inducers, including rifampin, rifabutin, carbamazepine, phenytoin, phenobarbital and the herbal supplement St John’s wort. Lower levels mean less protection for a transplant patient, which is why the label advises against combining sirolimus with strong inhibitors or inducers at all.

Other combinations matter too. Use with an ACE inhibitor has been linked to angioedema, sudden swelling of the face, lips, tongue or airway. Cyclosporine changes sirolimus exposure, which is why the label sets out how the two doses are spaced. Stacking additional immunosuppressants adds infection risk. Bring a complete list of prescriptions, over the counter products and supplements to any consultation, and ask a pharmacist to screen the whole list rather than just the obvious drugs.

What a month costs without insurance, and what moves that number

Two separate costs sit behind this prescription, and blending them is the most common budgeting mistake. One is the medicine itself from a pharmacy. The other is the program that writes and monitors the prescription: intake, clinician time, bloodwork and refills.

Where telehealth programs publish a self-pay figure for this molecule, the lowest tracked monthly price is and the tracked median is . Those are cash-pay program prices, not pharmacy invoices, and advertised prices move, so treat any figure as a starting point rather than a quote. Programs that can bill insurance instead charge a plan or membership fee, which sits apart from copays and deductibles that vary by plan and by state.

What actually moves your monthly total:

• Brand versus generic. Generic sirolimus is usually the cheaper route; brand-name tablets sit higher.
• Dose and pill count. Tablets come in more than one strength, and the monthly total depends on how many you take and how often.
• Pharmacy. Cash prices for the same generic differ between retail chains, mail order and discount programs.
• What the program bundles. Some fees include visits, labs and follow-up. Others charge for each separately, and lab panels are the item that surprises people.
• Intro versus renewal. A first-month rate is not always the ongoing rate. Ask what month four costs.

Because this is a long-term prescription, a monthly figure understates the real commitment. Multiply it out before you decide anything.

On coverage, plans generally follow approved indications. Transplant and LAM prescriptions are the ones an insurer expects to see; off-label longevity use is usually paid out of pocket. Prior authorization is common for specialty prescriptions, and denials are routine rather than unusual, so ask your plan to confirm in writing what it will pay at your dose and diagnosis. Independent policy research explains why formulary and off-label rules differ so much between plans. If you want to see how a cost breakdown is laid out before you request one, our Free Savings Report example shows the structure, and the Free Health Calculators page collects the cost and lab tools in one place.

How telehealth programs prescribe it, and what varies between them

Longevity-focused telemedicine has made off-label access far easier than it used to be. Standards vary widely between programs, and the differences are the whole story. Before you sign up, compare:

• Screening. Does the program require baseline bloodwork before writing a prescription, and which panels?
• Prescriber transparency. Can you see who is prescribing, their license and state, and reach them with a question?
• Protocol. Is there a documented dosing and monitoring plan, and a written path for handling side effects?
• Follow-up. How often do labs repeat, and are follow-up visits included or billed?
• Pharmacy. Which licensed pharmacy fills the prescription, and is it standard generic tablets?
• State availability. Telemedicine prescribing depends on clinician licensure in the state where you live.
• Money mechanics. Membership length, cancellation terms and refund policy.

Those seven questions travel well across categories. The same discipline used to sort weight programs in our Comparing GLP-1 Telehealth Programs guide applies here: read what the fee includes, then read what it excludes. For a program-by-program view you can work through the Telehealth Provider Directory, and the Scoring Methodology page sets out what each score dimension measures. Cost patterns in another off-label-heavy category are worth a look too, since Compounded Versus Brand Semaglutide shows how far pricing can spread around a single molecule.

Questions to ask a clinician, and when to seek care

Bring a written list. Off-label prescribing rewards patients who ask precise questions.

1. Why this medicine for me, and what alternatives would you consider first?
2. Is my use on-label or off-label, and what evidence supports it in my situation?
3. What dose and schedule, and how did you choose them?
4. Which baseline labs do I need, how often do they repeat, and do I get the results?
5. Are we monitoring drug levels in blood, and what range are we aiming for?
6. Which of my current medicines, supplements and foods interact?
7. Which side effects mean stop and call you, and how do I reach you after hours?
8. What is the plan if I need surgery, a vaccine or antibiotics?
9. What is my total monthly cost, including labs, visits and refills?
10. Under what circumstances would we stop?

Get medical help promptly for signs of infection such as fever, chills or a sore throat that will not settle, for new or worsening shortness of breath or a persistent dry cough, for mouth ulcers that stop you eating or drinking, for a wound that will not heal or turns red and warm, for unusual bruising or bleeding, for a big drop in how much you urinate, or for new or changing skin lesions. Swelling of the face, lips or tongue, hives or